Celiac.com Sponsor (A1):

Celiac.com Sponsor (A1-m):

  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.

    💬

    • Sign In
    • Sign Up

  • Record is Archived

    This article is now archived and is closed to further replies.

    Scott Adams

    Numerate Awarded Phase 1 NIH Grant to Support Design of New Therapies for Celiac Disease

    Scott Adams

    By Scott Adams •

    0
    Reviewed and edited by a celiac disease expert.

    Celiac.com 03/19/2009 - Numerate Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today it has received a Phase 1 grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH). The Small Business Technology Transfer (STTR) award, entitled “Drug Engineering of Transglutaminase 2 Inhibitors,” will be used to support a research collaboration between Numerate and the laboratory of Chaitan Khosla, Ph.D., the Wells H. Rauser and Harold M. Petiprin Professor of Chemical Engineering and Chemistry at Stanford University.

    “This NIH Phase 1 STTR award validates the attractiveness of Numerate’s drug engineering process for the design of new small molecule drugs,” stated John Griffin, Ph.D., Numerate’s chief scientific officer and principal investigator of the project. “In addition, it recognizes the potential of transglutaminase 2 inhibitors for the treatment of Celiac Sprue. Professor Khosla is a leader in Celiac disease research, and we are pleased to have the support of the NIH in our collaboration with him and his laboratory.”


    Celiac.com Sponsor (A12):




    Celiac.com Sponsor (A12-m):



    Professor Khosla, who will serve as co-investigator for the STTR research project, added, “Transglutaminase 2 is central to the pathophysiology of Celiac Sprue, and offers a compelling target for a disease for which no pharmacotherapy currently exists. I look forward to having Numerate apply its breakthrough technology to this important problem.”

    Celiac Sprue, also known as celiac disease, is an autoimmune disorder of the small intestine involving intolerance to gluten proteins found in wheat and other grains.

    About Numerate

    Numerate is a privately held biotechnology company that has developed and extensively validated a drug engineering process that rapidly and cost-effectively delivers small molecule drug candidates optimized for efficacy, safety, and patentability. Numerate’s drug engineering process combines advances in computer science, statistics, and molecular modeling to address, in parallel, the factors that determine the success and failure of a drug. Numerate applies this proprietary process to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical and biotechnology fields. For more information, please visit www.numerate.com.

    0
    Go to articles

    User Feedback

    Recommended Comments

    There are no comments to display.



    Guest
    This is now closed for further comments

  • Join eNewsletter

  • About Me

    Scott Adams

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.

  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):



    Celiac.com Sponsors (A17-m):



  • Related Articles

    Scott Adams
    The following is from a talk given at the Gluten Intolerance Group Annual Educational Seminar on April 1, 1995 by Dr. Alessio Fasano, Pediatric Gastroenterologist, University of Maryland School of Medicine which was also reported in the May 1995 issue of the GIG Newsletter. The findings of these experts indicate that the incidence of celiac disease in the general population could be as high as 1 in 300-500 people when one takes into account all forms of the disease. Here is a report of the meeting:
    The question which was brought up was How prevalent is celiac disease?. Although there is much data on the incidence of celiac disease that has...
    Jefferson Adams
    Celiac.com 09/28/2012 - Two researchers recently set out to study gluten sensitivity in people without celiac disease. The study was conducted by A. Di Sabatino A, and G.R. Corazza of the Centro per lo Studio e la Curia della Mallatia Celiaca at the Fondazione IRCCS Policlinico San Matteo at the University of Pavia in Italy.
    A number of studies support the existence non-celiac gluten sensitivity, which can be marked by both internal and external symptoms in individuals with normal small-bowel mucosa and negative results on serum anti-transglutaminase and anti-endomysial antibody testing. These symptoms are very similar to traditional celiac disease ...
    Jefferson Adams
    Celiac.com 11/22/2013 - Timing of gluten introduction has been associated with the risk of celiac disease in children, but the best time window for gluten introduction had remained unknown.
    In order to determine the optimal time window for gluten introduction in children, a team of researchers recently set out to assess the effect of age at first gluten consumption on the risk of celiac disease, and to adjust their data for continued breastfeeding.
    The research team included Ketil Størdal, MD, PhD, Richard A. White, PhD, and Merete Eggesbø, MD, PhD. They are variously affiliated with the Norwegian Institute of Public Health, Oslo, Norway; and Ø...
    Jefferson Adams
    Celiac.com 07/02/2014 - Each year, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, acetaminophen, and aspirin, send more than 100,000 people to the hospital, and cause over 16,000 deaths. These drugs are marketed under brand names such as Advil and aspirin, among others.
    In some ways, these findings are unsurprising. Studies from as far back as the 1980s have shown that “NSAIDs…disrupt intestinal integrity and long term treatment leads to inflammation of the small intestine.”
    Recently, a group of researchers reviewed study data from the last 20 years, and found that NSAIDs increase the likelihood of leaky gut syndrome.
    Acco...